IntraLase and Tissue Banks International Announce Installation of Femtosecond Laser at The National Eye Bank Center; TBI Will Be First to Use Laser for Large-Scale Preparation of Corneal Allografts.

IRVINE, Calif. -- IntraLase Corp. (NASDAQ:ILSE) and Tissue Banks International are pleased to announce the execution of an agreement to install an IntraLase FS laser for the preparation of corneal allografts at The National Eye Bank Center, TBI's new state-of-the-art facility in Memphis, Tenn. TBI will be the first large-scale eye bank organization to use the IntraLase FS (femtosecond) laser for preparation of corneal allografts for transplant.

The laser will be used to prepare allografts for posterior lamellar, anterior lamellar, and full thickness corneal transplants. Initial clinical work suggests that allografts prepared with IntraLase's femtosecond laser are stronger than those prepared with traditional penetrating keratoplasty, with less induction of astigmatism.

"We are very excited about this new application for the IntraLase femtosecond laser and delighted to see it utilized by TBI at The National Eye Bank Center," said Bernard Haffey, executive vice president and chief commercial officer of IntraLase. "Based on initial results with other donor bank users, we believe that corneal surgeons will be pleased with the advantages for their patients provided by a precisely prepared corneal allograft," Haffey explained.

"TBI is proud to be on the cutting edge of eye-banking with the installation of the femtosecond laser," said Gerald Cole, president and CEO of Tissue Banks International. "The preparation of precision-cut corneal allografts was one of the primary reasons we established The National Eye Bank Center. The efficiencies of our centralized processing and the transportation advantages of our Memphis location mean we can provide surgeons with their requested allografts quickly."

Beyond the installation of the femtosecond laser, IntraLase and Tissue Banks International have plans to collaborate on future applications and improvements as part of both TBI's and IntraLase's commitment to maximizing the benefits of this exciting technology.

The femtosecond laser is an extremely precise laser that received FDA clearance for the preparation of corneal allografts on Sept. 7, 2005. The ultrashort pulses the laser uses to cut tissue are too brief to transfer heat or shock, which means that cutting occurs with virtually no damage to surrounding material.

The National Eye Bank Center is a state-of-the-art facility designed to centralize the screening, evaluation, and shipping of eye tissue for sight-restoring corneal transplant surgery. The first such Center in the world, the multi-million dollar project will offer surgeons and their patients the largest concentration of ocular tissue and pre-cut grafts for ocular surgery. The Center ensures tissue's safety, quality, and rapid and efficient distribution to surgeons and researchers in the U.S. and overseas.

About IntraLase:

IntraLase designs, develops and manufactures an ultra-fast laser, related software and disposable devices used to create a corneal flap, the first step in LASIK surgery for the correction of vision. The company's products improve the safety, precision and visual results of LASIK procedures by providing a computer-controlled laser solution in place of the hand-held mechanical, metal-bladed microkeratome traditionally used to create corneal flaps. IntraLase lasers are also used in surgical approaches to the treatment of diseased corneas. The company's lasers and disposable per procedure patient interfaces are presently marketed throughout the United States and 21 other countries. IntraLase has headquarters and manufactures its products in Irvine. For additional information, visit the company's Web site: www.intralase.com.

About TBI:

Non-profit TBI/Tissue Banks International, founded as a single eye bank in 1962, today is a far-reaching network of associated eye and tissue banks throughout the United States and around the world. Providing nearly 10,000 corneas annually, TBI is the largest singular provider of ocular tissue in the world. For additional information about TBI and The National Eye Bank Center, visit TBI's Web site: www.tbionline.org.

Forward-Looking Statements:

Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," or "may." Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Those risks and uncertainties include, but are not limited to: the degree of continued acceptance of LASIK surgery; potential complications revealed by long-term follow up; the extent of adoption of our product offering by LASIK surgeons; general economic conditions; changes in federal tax laws governing the ability of potential LASIK patients to use pre-tax dollars to pay for LASIK surgery; the scope of government regulation applicable to our products; patients' willingness to pay for LASIK surgery; our ability to compete against our competitors; the effectiveness of our measures to ensure full payment of procedure fees; the occurrence and outcome of product liability suits against us; our ability to adequately protect our intellectual property; whether we become subject to claims of infringement or misappropriation of the intellectual property rights of others; the continued availability of supplies from single-source suppliers and manufacturers of our key laser components; the ability of our managers, operations, and facilities to manage our growth; the success of our expansion into markets outside the United States; whether we lose any of our key executives or fail to attract qualified personnel; or if our new products or applications fail to become commercially viable.

Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on form 10-Q for the period ending June 30, 2005, as filed with the Securities and Exchange Commission on Aug. 10, 2005.

These forward-looking statements are made only as of the date of this press release, and the company assumes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.